StockNote
DPP
Dong Nai Pharmaceutical Joint Stock Company (DPP) was established in 1996 on the basis of a merger of two companies: Dong Nai Pharmaceutical Company and Dong Nai Pharmaceutical and Medical Supplies Company. In 2006, the company moved to operate under the model of a joint stock company. The company's business is mainly focused on the production and trading of pharmaceuticals produced by the company. In addition, the company also directly imports and deals in pharmaceuticals, raw materials for production and entrusted import of pharmaceuticals, medical machinery (ultrasound machines...). The proportion of revenue from the field of trade and import and export of pharmaceutical drugs accounts for an average of about 70-80% of the company's total annual sales revenue.
DPP currently has a market capitalization of roughly VND 80 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 7,3x is 5% below its own 6-year average (7,7x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 1,4x, 17% above its multi-year average of 1,2x. Return on equity (ROE) is at 18,5%, up from 16,2% the year before. Its debt-to-equity ratio of 0x is low, reflecting a conservative capital structure. In 2025, revenue fell 5% year-on-year while after-tax profit grew 23%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Not enough data for this period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.